• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

Recent Advances in the Study of (4-iodo-1H-imidazol-2-yl)methanamine (CAS: 2090321-57-4)

In recent years, (4-iodo-1H-imidazol-2-yl)methanamine (CAS: 2090321-57-4) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This heterocyclic amine, characterized by its imidazole core and iodine substitution, has shown promising potential in various therapeutic applications. The compound's unique structural features make it a valuable scaffold for drug discovery, particularly in the development of novel enzyme inhibitors and receptor modulators.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the synthesis and biological evaluation of (4-iodo-1H-imidazol-2-yl)methanamine derivatives as potential kinase inhibitors. The research team employed a structure-activity relationship (SAR) approach to optimize the compound's potency and selectivity. Their findings demonstrated that modifications at the methanamine moiety significantly influenced the compound's binding affinity to target kinases, with certain derivatives showing nanomolar inhibitory activity.

Another significant development comes from a 2024 Nature Chemical Biology publication, where researchers investigated the compound's role in modulating protein-protein interactions. The study revealed that (4-iodo-1H-imidazol-2-yl)methanamine could serve as a molecular glue, facilitating the formation of ternary complexes between specific proteins. This property opens new avenues for targeting previously undruggable protein interfaces in various disease pathways.

From a synthetic chemistry perspective, recent advancements have focused on developing more efficient routes to produce (4-iodo-1H-imidazol-2-yl)methanamine and its derivatives. A 2023 Organic Letters paper described a novel palladium-catalyzed cross-coupling strategy that significantly improved the yield and purity of the compound, making it more accessible for large-scale biological studies.

The pharmacological profile of (4-iodo-1H-imidazol-2-yl)methanamine has also been the subject of recent investigations. Preclinical studies have demonstrated favorable pharmacokinetic properties, including good oral bioavailability and blood-brain barrier penetration in animal models. These characteristics make the compound particularly interesting for central nervous system (CNS) drug development.

Looking forward, several research groups are exploring the potential of (4-iodo-1H-imidazol-2-yl)methanamine in targeted drug delivery systems. Its chemical structure allows for easy conjugation with various drug molecules and nanoparticles, potentially enabling more precise therapeutic interventions with reduced off-target effects.

While these developments are promising, challenges remain in fully understanding the compound's mechanism of action and potential toxicity profiles. Ongoing research efforts are addressing these questions through comprehensive in vitro and in vivo studies, with results expected to be published in the coming year.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)